DOJ Gives Alibaba Non-Prosecution Deal, Downgrades Drug Safety Felonies
The Justice Department reached a non-prosecution agreement with Alibaba that downgrades alleged Food, Drug and Cosmetic Act felonies to misdemeanors and requires about $600 million in penalties and forfeitures.[1]
Career prosecutors had recommended a deferred prosecution that would have required Alibaba to admit to felony FDCA violations, but DOJ leadership approved a non-prosecution agreement limited to misdemeanors.[1] The resolution also covers Alibaba's U.S. payment processor AUS Merchant Services and is cited by sources as one of several recent instances where DOJ leadership scaled back or dropped major health-and-safety prosecutions.[1]
Between January 2016 and December 2024, merchants on Alibaba's platforms completed roughly 80,000 sales of illegal pharmaceuticals, controlled substances, listed chemicals and pill presses imported into the United States. Their combined gross merchandise value exceeded $200 million.
Career prosecutors said they uncovered evidence showing Alibaba knowingly allowed dangerous drugs to reach U.S. consumers, yet the case concluded without felony charges.[1] Critics on social media called the $600 million deal a corporate franchise fee and said it lacks executive accountability, while law enforcement emphasized the agreement's compliance reforms as a signal to global e-commerce platforms.
The mainstream summary does not mention the significant implications of the non-prosecution agreement, which critics argue effectively serves as a corporate franchise fee for Alibaba, given the scale of the 80,000 illegal sales over eight years and the absence of personal accountability for executives. BlueSky users have pointed out that the $600 million settlement fails to deter future violations, as Alibaba is not required to plead guilty or face executive charges, raising concerns about the effectiveness of the agreement in holding corporations accountable for public health and safety violations.
Additionally, while the summary notes the compliance reforms required by the DOJ, it overlooks the broader context of declining strict criminal prosecutions under the Federal Food, Drug, and Cosmetic Act. Recent reports indicate that such prosecutions dropped sharply from 14 in 2024 to only four in 2025, suggesting a troubling trend in how health and safety violations are handled by federal authorities. This shift may reflect a new corporate enforcement policy that prioritizes voluntary compliance over punitive measures, which could undermine efforts to prevent illegal product sales in the future.[2]
Show source details & analysis (1 source)
📊 Relevant Data
Between January 2016 and December 2024, Alibaba failed to prevent merchants on its platforms from completing approximately 80,000 sales of illegal pharmaceuticals, controlled substances, listed chemicals, and pill presses imported into the United States, with combined gross merchandise value exceeding $200 million.
Alibaba Group and AUS Merchant Services Agree to Pay $600 Million to Resolve Allegations They Failed to Prevent Sale and Importation of Illegal Pharmaceuticals and Other Prohibited Items into the United States — U.S. Department of Justice
Under the Federal Food, Drug, and Cosmetic Act, a first violation of prohibited acts is generally a misdemeanor punishable by up to one year imprisonment and a $1,000 fine, while a repeat violation or one committed with intent to defraud or mislead is a felony punishable by up to three years imprisonment and a $10,000 fine (21 U.S.C. § 333).
21 U.S. Code § 333 - Penalties — U.S. Code via Cornell Law School Legal Information Institute
📌 Key Facts
- For roughly eight years, Alibaba and its U.S. processor AUS Merchant Services failed to prevent dangerous drugs, chemicals and pill presses from being sold to American customers.
- Career prosecutors recommended a deferred prosecution agreement in which Alibaba would admit to felony Food, Drug and Cosmetic Act violations, but DOJ leadership recently approved a non‑prosecution agreement limited to misdemeanors.
- The resolution includes about $600 million in penalties and forfeitures and is cited by sources as one of several recent instances where DOJ leadership scaled back or dropped major health-and-safety prosecutions.
📰 Source Timeline (1)
Follow how coverage of this story developed over time